| Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility A Sazonovs, CR Stevens, GR Venkataraman, K Yuan, B Avila, MT Abreu, ... Nature genetics 54 (9), 1275-1283, 2022 | 123 | 2022 |
| Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biologic therapies: a national cohort study C Liefferinckx, B Verstockt, A Gils, M Noman, C Van Kemseke, E Macken, ... Journal of Crohn's and Colitis 13 (11), 1401-1409, 2019 | 109 | 2019 |
| Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy U Kopylov, J Hanzel, C Liefferinckx, D De Marco, N Imperatore, N Plevris, ... Alimentary pharmacology & therapeutics 52 (1), 135-142, 2020 | 74 | 2020 |
| Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance C Liefferinckx, C Minsart, A Cremer, L Amininejad, V Tafciu, ... European journal of gastroenterology & hepatology 31 (4), 478-485, 2019 | 36 | 2019 |
| Variability of faecal calprotectin in inflammatory bowel disease patients: an observational case-control study A Cremer, J Ku, L Amininejad, MR Bouvry, F Brohet, C Liefferinckx, ... Journal of Crohn's and Colitis 13 (11), 1372-1379, 2019 | 32 | 2019 |
| New insights in acetaminophen toxicity: HMGB1 contributes by itself to amplify hepatocyte necrosis in vitro through the TLR4-TRIF-RIPK3 axis C Minsart, C Liefferinckx, A Lemmers, C Dressen, E Quertinmont, ... Scientific reports 10 (1), 5557, 2020 | 29 | 2020 |
| Analysis of genes associated with monogenic primary immunodeficiency identifies rare variants in XIAP in patients with Crohn’s disease L Amininejad, B Charloteaux, E Theatre, C Liefferinckx, J Dmitrieva, ... Gastroenterology 154 (8), 2165-2177, 2018 | 29 | 2018 |
| Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group]. Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed … C Liefferinckx, B Verstockt, A Gils, M Noman, C Van Kemseke, E Macken, ... J Crohns Colitis 13 (11), 1401-1409, 2019 | 24 | 2019 |
| Infliximab trough levels at induction to predict treatment failure during maintenance C Liefferinckx, C Minsart, JF Toubeau, A Cremer, L Amininejad, ... Inflammatory bowel diseases 23 (8), 1371-1381, 2017 | 21 | 2017 |
| Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility A Sazonovs, CR Stevens, GR Venkataraman, K Yuan, B Avila, MT Abreu, ... medRxiv, 2021.06. 15.21258641, 2021 | 13 | 2021 |
| Effectiveness of third-class biologic treatment in Crohn’s disease: a multi-center retrospective cohort study A Albshesh, J Taylor, EV Savarino, M Truyens, A Armuzzi, DG Ribaldone, ... Journal of clinical medicine 10 (13), 2914, 2021 | 12 | 2021 |
| Introduction of subcutaneous infliximab CT-P13 and vedolizumab in clinical practice: a multi-stakeholder position statement highlighting the need for post-marketing studies L Fierens, C Liefferinckx, E Hoefkens, T Lobatòn, E Dreesen, J Sabino, ... Journal of Crohn's and Colitis 16 (7), 1059-1069, 2022 | 10 | 2022 |
| Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases C Liefferinckx, B Verstockt, A Gils, S Tops, W Van Moerkercke, S Vermeire, ... United European gastroenterology journal 7 (6), 750-758, 2019 | 10 | 2019 |
| Collecting new peak and intermediate infliximab levels to predict remission in inflammatory bowel diseases C Liefferinckx, J Bottieau, JF Toubeau, D Thomas, JF Rahier, E Louis, ... Inflammatory bowel diseases 28 (2), 208-217, 2022 | 9 | 2022 |
| New approach to determine the healthy immune variations by combining clustering methods C Liefferinckx, Z De Grève, JF Toubeau, H Perée, E Quertinmont, V Tafciu, ... Scientific reports 11 (1), 8917, 2021 | 6 | 2021 |
| P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients C Liefferinckx, M Fassin, D Thomas, C Minsart, A Cremer, L Amininejad, ... Journal of Crohn's and Colitis 14 (Supplement_1), S331-S333, 2020 | 6 | 2020 |
| Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). D Franchimont, M Ferrante, E Louis, M De Vos, O Dewit, P Van Hootegem, ... Acta gastro-enterologica Belgica 81 (1), 2018 | 6 | 2018 |
| Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn’s disease C Liefferinckx, A Hubert, D Thomas, J Bottieau, C Minsart, A Cremer, ... Digestive and Liver Disease 55 (3), 366-372, 2023 | 5 | 2023 |
| toward the genetic architecture of disease severity in inflammatory bowel diseases C Liefferinckx, D Franchimont Inflammatory bowel diseases 24 (7), 1428-1439, 2018 | 5 | 2018 |
| Crohn’s disease-related ‘gastrocnemius myalgia syndrome’successfully treated with infliximab: a case report J Catherine, H Kadhim, F Lambot, C Liefferinckx, V Meurant, LO Sanchez World Journal of Gastroenterology 28 (7), 755, 2022 | 4 | 2022 |